DS

David Schenkein

Hematologist, General Partner and Co-Head Life Science @ GV,

Boston, Massachusetts

VC
Investor

Invests in

  • Min Investment:

    $250,000.00

  • Max Investment:

    $50,000,000.00

  • Target Investment:

    $25,000,000.00

Education

Lists including David

AM
AR
AB
AF

Based in Boston & Cambridge

668 people

AT
AS
AT
AH

All Series A Investors

14752 people

Investments

Delphia Therapeutics

Series A

Total Funding: $67M

Cerevance

Series B

Total Funding: $160M

EpiBiologics

Series A

Total Funding: $96M

Aera Therapeutics

Series B

Total Funding: $190M

Leyden Labs

Series A

Total Funding: $190M

Prime Medicine

Series A

Total Funding: $320M

Encoded Therapeutics

Series D

Total Funding: $240M

Work Experience

G
GV

2019

  • General Partner

    2019

R
Regeneron

2023

  • Board Member

    2023

TM
Tufts Medical Center

2009

  • Clinical Professor of Medicine

    2009

AP
Agios Pharmaceuticals

2009

  • Board Member

    2022

  • Chairperson of the Board

    2019 - 2022

  • CEO

    2009 - 2019

DT
Denali Therapeutics

2015

  • Board Member

    2015

G
Genentech

2006 - 2009

  • Senior Vice President, Clinical Hematology/Oncology

    2006 - 2009

Millennium Pharmaceuticals

2001 - 2006

  • Senior Vice President, Clinical Research

    2001 - 2006